A recent study by a team of Turkish scientists has sparked global interest after flagging a potential link between the Pfizer-BioNTech COVID-19 vaccine and eye-related side effects.
Specifically, the study highlights subtle but measurable changes in retinal blood vessels and corneal endothelial cells raising questions around the possible risk of Pfizer vaccine eye damage, though experts stress that such effects are rare and more research is needed.
What the Research Says
In a study involving 40 healthcare professionals, optical coherence tomography angiography (OCTA) revealed a significant decrease in retinal vascular density and increased retinal thickness just three days after vaccination changes that suggest possible inflammation or endothelial impact from the vaccine’s spike protein.
A related study monitored over 60 individuals and found transient alterations in retinal blood vessel density peaking at two weeks post‑vaccine, but returning to baseline by week four. No long-term damage was observed in healthy participants.
A broader review covering 49 studies and 130 cases found most ocular vascular events occurred within 5–10 days of vaccination, commonly affecting those older than 50. More cases were associated with Pfizer and AstraZeneca vaccines than others but experts note these events remain exceedingly rare and do not prove a causal relationship.
Case Examples
- A Turkish case report described a 56-year-old woman developing central retinal vein occlusion (CRVO) two days post‑Pfizer vaccine. While journal authorities ruled out other causes, the timing raised concerns about coagulation and inflammation effects.
- In Malaysia, a small series spanning four patients reported acute eye conditions such as uveitis, choroidal neovascularisation, and retinal pigment epitheliitis after both Pfizer and AstraZeneca vaccines. All patients eventually recovered with treatment.
Larger Context: Is There a Real Risk?
A global retrospective cohort study using electronic health records found a 2.19 fold higher risk of retinal vascular occlusion among vaccinated individuals over two years even after adjusting for age and health history.
That said, a JAMA Ophthalmology letter critiqued methodology biases and emphasized that actual causality remains unproven, and COVID‑19 itself poses a much greater clotting risk.
Most experts stress that ocular side effects are rare, and the benefits of vaccination reducing COVID‑19 deaths and severe disease still far outweigh the reported risks.
